OncoPrecision to Present ONC001, a First-in-Class ADC for Monocytic Leukemia, at 67th ASH Annual Meeting

OncoPrecision to Present ONC001 at ASH 2025

OncoPrecision Corporation, a leader in developing innovative antibody-based cancer therapies, recently announced that it will present its novel drug candidate, ONC001, at the 67th Annual Meeting and Exhibition of the American Society of Hematology (ASH), which will be held from December 6 to 9, 2025, in Orlando, Florida.

ONC001 is a first-in-class antibody-drug conjugate (ADC) specifically designed to target CD64, a myeloid receptor frequently found in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) subtypes, particularly those that are highly resistant. The ADC is the result of OncoPrecision's proprietary research platform that integrates extensive patient-derived biological data with advanced AI-driven high-throughput screening methods. This unique approach has allowed the identification of a lead antibody with a strong affinity for a previously neglected target molecule and the optimization of the ADC payload and linker chemistry. These innovations aim to minimize off-target toxicity and reduce collateral damage to normal hematopoiesis.

Currently, ONC001 is undergoing IND-enabling studies, representing a differentiated approach to overcoming the resistance mechanisms associated with monocytic leukemia. The preclinical data presented by Dr. Gastón Soria, co-founder and Chief Scientific Officer of OncoPrecision, will highlight the efficacy and selectivity of ONC001 in targeting cancer cells derived from patients, its robust activity in samples resistant to current standard therapies, and its promising efficacy demonstrated in various in vivo models.

Tarek Zaki, co-founder and CEO of OncoPrecision, expressed enthusiasm about the presentation: *